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It is now just over 1 year since I took over the Editorship of
Influenza and Other Respiratory Viruses (IRV). In that time,
there have been many changes to the journal and, of course,
in the wider world of respiratory viruses. I’d like to begin by
thanking my predecessor and the journal’s Founding Editor,
Dr. Alan Hampson. Alan set up, nurtured and grew IRV into
a vibrant and successful publication before officially handing
over the reins in early 2014. He remains on the team as one
of our Senior Editors. Indeed my task as Editor-in-Chief
would be impossible without the fantastic and dedicated
team of Senior Editors, Associate Editors and professional
staff at Wiley, who support me, and all of whom deserve
many personal thanks.
The challenges posed by respiratory viruses remain as
important as ever for global public health, and clinical
practice. In the aftermath of the 2009 pandemic, govern-
ments and public health agencies are wrestling with ‘pan-
demic fatigue’, austerity programmes (that limit the appetite
and ability to invest in pandemic preparedness), and a false
impression among some politicians that since the 2009
pandemic was rather mild and ‘not much to write home
about’, pandemic preparedness is in fact ‘no big deal’. In
amongst this mix are real issues pertaining to the ongoing
controversy about the effectiveness of antiviral drugs,1–3; and
the fact that current vaccine manufacturing platforms can
only offer commercial quantities of pandemic vaccine some
four to 6 months after a novel virus has emerged, thus
substantially reducing the overall public health benefits, even
though vaccines themselves are effective.4,5
Most public health agencies and individual experts,
consider the potential pandemic threat posed by influenza
A(H5N1) to be undiminished. But in addition, influenza A
(H7N9) is now, if anything, considered a higher potential
risk.6 Recent human cases of influenza A(H10N8),7 and A
(H5N6),8 further remind us that the risk assessment
landscape for influenza is constantly evolving and, in turn,
this demands constant vigilance from the public health and
scientific communities.
If one shifts the focus away from influenza, the ongoing
MERS-CoV outbreak in the Middle East, is also of
substantial concern, because despite its likely introduction
into humans via close contact with dromedary camels,9
nosocomial transmission appears to be a central con-
cern,10,11 case-fatality is high, household transmission is also
described,12 and there are currently no vaccines or specific
therapies available. Finally enterovirus D68 seems to be
emerging as a potentially important respiratory pathogen in
children.13
Seasonal influenza too, should not be overlooked as an
ongoing problem. In the northern hemisphere winter of
2014–15 we have experienced substantial influenza A(H3N2)
activity. Unfortunately this has coincided with a poorly
matched H3N2 vaccine component that has resulted in low
effectiveness against the circulating H3N2 strains in the
community.14 This has recently been linked to excess winter
mortality across Europe in the population aged 65 years and
over,15 illustrating that we need more broadly protective
vaccines, especially in the elderly.
From the journal’s perspective, to be in the best possible
position to respond to these emerging and sometimes fast-
moving threats, we have made some recent changes that
enable us to publish findings with minimal delay. For papers
of significant importance, we can offer a rapid peer-review
scheme, which should enable us to make a decision on a
manuscript within 14 days (or less). We have also improved
our arrangements for all accepted articles (whether fast-
tracked or not). Following acceptance, we can now publish
all articles, as unedited manuscripts, online within 1 week of
acceptance.
We have also reconsidered the arrangements for review
articles that we publish. We recognise that Systematic
Reviews and Meta-analyses have become a central part of
evidence synthesis in modern science and medicine. With
this has come the setting of standards for the conduct of such
work: the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines;16,17 and we now
require any systematic reviews that we accept to conform to
these principles. However, we shall continue to accept Expert
Commentary articles alongside as these continue to be
relevant and useful to our readers.
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Hopefully these changes, along with our now well-
established Open Access format will maintain the journal
as a vibrant publication that is relevant, and highly accessible,
to scientists and clinicians working in the field of respiratory
virus infection for the foreseeable future.
Rapid peer-review procedures
Authors have the option to request rapid peer-review. Papers
considered for rapid peer-review will need to be of
immediate relevance, interest, or importance to scientists,
clinicians, public health practitioners or policy makers,
usually in relation to a current or evolving event related to
respiratory virus activity. In general, papers that report data
more than 6 months old are unlikely to be considered
eligible. If your paper qualifies for rapid peer-review, the
journal will aim to have your paper turned round within
14 days. There is no additional charge for authors with rapid
peer-review.
Step #1 - Authors will need to contact the Editorial Office
irv.eo@wiley.com, at least 1 week before online submis-
sion with an abstract; list of authors; please ensure a
PRISMA checklist is completed if your paper is a
Systematic Review article; details of research funding
and disclosures of potential conflicts of interest should
also be included.
Step #2 - The Editors will confirm whether your paper will
qualify for rapid peer-review. The decision is final and
non-negotiable.
Step #3 - Submit the paper via the ScholarOne system.
Accepted articles
Accepted Articles have been accepted for publication and
undergone full peer review but have not been through the
copyediting, typesetting, pagination and proofreading pro-
cess. Accepted Articles are published online a few days after
final acceptance, appear in PDF format only, are given a
Digital Object Identifier (DOI), which allows them to be
cited and tracked, and are indexed by PubMed.
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